drugset / Trial / NCT03096054
A Phase I Trial of LY3143921 Hydrate in Solid Tumours
Non-randomizedSequentialOpen-labelTreatment
Summary
This clinical study looked at a drug called LY3143921 hydrate (a Cdc7 inhibitor) in adult patients with advanced solid tumours. The main aims were to find out the maximum dose of LY3143921 hydrate that could be given safely to patients, and to assess the potential side effects and how they could be treated.
Timeline
- Start
- 2017-06-21
- Primary completion
- 2025-04-09
- Completion
- 2025-04-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LY3143921 | Small molecule | — | Oral |